Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a Waltham, Massachusetts-based biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. News about Viridian often centers on its late-stage programs in thyroid eye disease (TED), regulatory milestones, clinical trial updates, and financing activities that support its pipeline and anticipated commercialization efforts.
Investors following VRDN news can expect frequent updates on veligrotug, Viridian’s intravenously delivered anti–IGF‑1R antibody for TED. Company announcements have highlighted the completion of two global phase 3 trials, THRIVE and THRIVE‑2, positive topline data, and the U.S. Food and Drug Administration’s acceptance of a Biologics License Application with Priority Review and a defined PDUFA target action date. News releases also discuss preparations for a potential commercial launch, including market access, medical affairs, and engagement with a core prescriber base.
Another key news theme is VRDN‑003 (elegrobart), a subcutaneous, half‑life extended anti‑IGF‑1R antibody in phase 3 trials REVEAL‑1 and REVEAL‑2 for active and chronic TED. Viridian’s press releases describe enrollment progress, anticipated topline data timing, and the design of VRDN‑003 for subcutaneous administration in a low‑volume autoinjector with every‑four‑week or every‑eight‑week dosing. Updates on Viridian’s FcRn inhibitor portfolio—including VRDN‑006 and VRDN‑008—cover proof‑of‑concept IgG reduction data, investigational new drug (IND) submissions, and preclinical head‑to‑head findings.
VRDN news also frequently includes corporate and financial developments, such as public equity offerings, royalty financing agreements, amended credit facilities, and collaboration and license agreements like the partnership with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. These disclosures provide context on how Viridian plans to fund its clinical programs and potential commercial launches. For a comprehensive view of Viridian’s evolving TED pipeline, autoimmune disease programs, and capital strategy, readers can review the ongoing stream of press releases, earnings updates, and SEC-reported events associated with the VRDN ticker.
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company specializing in rare diseases, has announced the approval of inducement grants to 4 new employees. The grants consist of non-qualified stock options to purchase 181,450 shares of common stock, with an exercise price equal to the closing price on August 1, 2025.
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The grants were made outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms and conditions.
Notably, Viridian is advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive Phase 3 trial results. The company is also developing novel FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune diseases.
Viridian Therapeutics (NASDAQ:VRDN) has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical for the development and commercialization of veligrotug and VRDN-003 in Japan. The deal includes an upfront payment of $70 million and potential additional payments of up to $315 million in milestones.
Both compounds are anti-IGF-1R antibodies targeting thyroid eye disease (TED), with VRDN-003 being a potential best-in-class subcutaneous treatment. The agreement grants Kissei exclusive rights in Japan, with Kissei responsible for all development, regulatory, and commercialization activities. Viridian will receive tiered royalties ranging from the 20s to mid-30s percent on net sales in Japan.
The collaboration leverages Viridian's TED portfolio and Kissei's expertise in rare disease commercialization in Japan. Veligrotug has already demonstrated positive topline data in the THRIVE and THRIVE-2 Phase 3 trials.
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company focused on rare diseases, announced an inducement grant of 175,000 stock options to a new employee on July 1, 2025. The grant, approved under Nasdaq Rule 5635(c)(4), will vest over four years with a 25% initial vest after one year.
The company is currently advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive Phase 3 trial results. Additionally, Viridian is developing novel FcRn inhibitors VRDN-006 and VRDN-008 for potential autoimmune disease treatments.
Viridian Therapeutics (NASDAQ: VRDN) has received FDA Breakthrough Therapy Designation for veligrotug, its lead drug candidate for treating Thyroid Eye Disease (TED). The designation was granted based on veligrotug's consistent improvement in diplopia and rapid proptosis response in clinical trials. The drug successfully met all primary and secondary endpoints in the THRIVE and THRIVE-2 phase 3 clinical trials for both active and chronic TED.
Notably, veligrotug is the first and only drug candidate in chronic TED to show statistically significant improvement in diplopia in a global phase 3 trial. The company plans to submit a Biologics License Application (BLA) in H2 2025, with a targeted U.S. launch in 2026. The breakthrough designation supports eligibility for Priority Review. The TED market represents significant commercial potential, with U.S. revenues of approximately $2 billion in 2024.
Viridian Therapeutics (VRDN) has granted stock options for 204,150 shares to 13 new employees as inducement awards. The options, approved on May 1, 2025, will vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months. The exercise price equals the closing price on the grant date.
The company is advancing multiple treatments for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003. Both programs have shown positive results in Phase 3 trials. Additionally, Viridian is developing novel FcRn inhibitors (VRDN-006 and VRDN-008) for potential autoimmune disease treatments.
Viridian Therapeutics (Nasdaq: VRDN) has appointed Jeff Ajer to its Board of Directors. Ajer brings over 25 years of experience in rare diseases and specialty medicines commercialization, most recently serving as Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical.
The appointment comes as Viridian advances veligrotug, its thyroid eye disease (TED) treatment candidate, towards BLA submission. The company also announced inducement grants of stock options to purchase 220,750 shares for 14 new employees, vesting over four years.
Viridian is currently conducting pivotal programs including two global phase 3 trials (THRIVE and THRIVE-2) for veligrotug, which have met all primary and secondary endpoints. Additionally, the company is advancing VRDN-003 in two phase 3 trials (REVEAL-1 and REVEAL-2) as a potential subcutaneous TED therapy, alongside developing novel FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune diseases.